Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Langue: | |
| Publié: |
Zenodo
2025
|
| Accès en ligne: | https://doi.org/10.5281/zenodo.16928984 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Table des matières:
- <p dir="ltr">Breast cancer can be distinguished into two broad groups, luminal and basal, based on cytologic, morphologic, cytoskeletal and differentiation-based features. While luminal breast cancers can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2) and targeted accordingly clinically, basal-like breast cancers cannot. Inadequate long-term control of disease (e.g., partial response [PR] or recurrence/relapse) reflects limited effectiveness of existing drugs that treat basal subtype disease. Here we utilized whole transcriptome technologies (5, 6) to define the basal-like breast cancer kinome and phosphatome by measuring total transcription in the primary tumors of humans with basal-like as compared to luminal A and luminal B breast cancer to identify basal-like signaling features. We describe one member of a group of kinases up-regulated and differentially expressed in human basal-like breast cancer, STK32C, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of basal subtype breast cancer. </p>